1. Cardiac Remodeling in the Mouse Model of Marfan Syndrome Develops Independently from Aortic and Valvular Abnormalities

    Biophysical Journal 108(2):595a (2015)

  2. Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

    Current Therapeutic Research 76:110 (2014) PMID 25408789

    We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare the sonography data with those from postmortem histomorphologic analyses to have a practical reference for...
  3. Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

    Current Therapeutic Research 76:110 (2014) PMID 25408789 PMCID PMC4229510

    We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare the sonography data with those from postmortem histomorphologic analyses to have a practical reference for...
  4. Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

    Current Therapeutic Research 76:110 (2014) PMID 25408789 PMCID PMC4229510

    We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare the sonography data with those from postmortem histomorphologic analyses to have a practical reference for...
  5. Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

    Current Therapeutic Research 76:110 (2014) PMID 25408789 PMCID PMC4229510

    We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare the sonography data with those from postmortem histomorphologic analyses to have a practical reference for...
  6. Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

    Current Therapeutic Research 76:110 (2014) PMID 25408789 PMCID PMC4229510

    We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare the sonography data with those from postmortem histomorphologic analyses to have a practical reference for...
  7. Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

    Current Therapeutic Research 76:110 (2014) PMID 25408789 PMCID PMC4229510

    We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare the sonography data with those from postmortem histomorphologic analyses to have a practical reference for...
  8. The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth.

    Klinische Wochenschrift 91(12):1369 (2013) PMID 24132651 PMCID PMC3846495

    Signaling of the receptor for advanced glycation end products (RAGE) has been implicated in the development of injury-elicited vascular complications. Soluble RAGE (sRAGE) acts as a decoy of RAGE and has been used to treat pathological vascular conditions in animal models. However, previous stud...
  9. The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth.

    Klinische Wochenschrift 91(12):1369 (2013) PMID 24132651 PMCID PMC3846495

    Signaling of the receptor for advanced glycation end products (RAGE) has been implicated in the development of injury-elicited vascular complications. Soluble RAGE (sRAGE) acts as a decoy of RAGE and has been used to treat pathological vascular conditions in animal models. However, previous stud...
  10. The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth.

    Klinische Wochenschrift 91(12):1369 (2013) PMID 24132651 PMCID PMC3846495

    Signaling of the receptor for advanced glycation end products (RAGE) has been implicated in the development of injury-elicited vascular complications. Soluble RAGE (sRAGE) acts as a decoy of RAGE and has been used to treat pathological vascular conditions in animal models. However, previous stud...
  11. Gi-biased β2AR signaling links GRK2 upregulation to heart failure.

    Circulation Research 110(2):265 (2012) PMID 22179058 PMCID PMC3282829

    Phosphorylation of β(2)-adrenergic receptor (β(2)AR) by a family of serine/threonine kinases known as G protein-coupled receptor kinase (GRK) and protein kinase A (PKA) is a critical determinant of cardiac function. Upregulation of G protein-coupled receptor kinase 2 (GRK2) is a well-established...
  12. Gi-biased β2AR signaling links GRK2 upregulation to heart failure.

    Circulation Research 110(2):265 (2012) PMID 22179058 PMCID PMC3282829

    Phosphorylation of β(2)-adrenergic receptor (β(2)AR) by a family of serine/threonine kinases known as G protein-coupled receptor kinase (GRK) and protein kinase A (PKA) is a critical determinant of cardiac function. Upregulation of G protein-coupled receptor kinase 2 (GRK2) is a well-established...
  13. Striated muscle tropomyosin isoforms differentially regulate cardiac performance and myofilament calcium sensitivity.

    Journal of Muscle Research and Cell Motility 31(3):227 (2010) PMID 20803058 PMCID PMC3805252

    Tropomyosin (TM) plays a central role in calcium mediated striated muscle contraction. There are three muscle TM isoforms: alpha-TM, beta-TM, and gamma-TM. alpha-TM is the predominant cardiac and skeletal muscle isoform. beta-TM is expressed in skeletal and embryonic cardiac muscle. gamma-TM is ...
  14. Striated muscle tropomyosin isoforms differentially regulate cardiac performance and myofilament calcium sensitivity.

    Journal of Muscle Research and Cell Motility 31(3):227 (2010) PMID 20803058 PMCID PMC3805252

    Tropomyosin (TM) plays a central role in calcium mediated striated muscle contraction. There are three muscle TM isoforms: alpha-TM, beta-TM, and gamma-TM. alpha-TM is the predominant cardiac and skeletal muscle isoform. beta-TM is expressed in skeletal and embryonic cardiac muscle. gamma-TM is ...
  15. Molecular and functional characterization of a novel cardiac-specific human tropomyosin isoform.

    Circulation 121(3):410 (2010) PMID 20065163 PMCID PMC2822663

    Tropomyosin (TM), an essential actin-binding protein, is central to the control of calcium-regulated striated muscle contraction. Although TPM1alpha (also called alpha-TM) is the predominant TM isoform in human hearts, the precise TM isoform composition remains unclear. In this study, we quantif...
  16. Molecular and functional characterization of a novel cardiac-specific human tropomyosin isoform.

    Circulation 121(3):410 (2010) PMID 20065163 PMCID PMC2822663

    Tropomyosin (TM), an essential actin-binding protein, is central to the control of calcium-regulated striated muscle contraction. Although TPM1alpha (also called alpha-TM) is the predominant TM isoform in human hearts, the precise TM isoform composition remains unclear. In this study, we quantif...
  17. An internal domain of beta-tropomyosin increases myofilament Ca(2+) sensitivity.

    American Journal of Physiology - Heart and Circ... 297(1):H181 (2009) PMID 19429821 PMCID PMC2711731

    Tropomyosin (TM) is involved in Ca(2+)-mediated muscle contraction and relaxation in the heart. Striated muscle alpha-TM is the major isoform expressed in the heart. The expression of striated muscle beta-TM in the murine myocardium results in a decreased rate of relaxation and increased myofila...
  18. An internal domain of beta-tropomyosin increases myofilament Ca(2+) sensitivity.

    American Journal of Physiology - Heart and Circ... 297(1):H181 (2009) PMID 19429821 PMCID PMC2711731

    Tropomyosin (TM) is involved in Ca(2+)-mediated muscle contraction and relaxation in the heart. Striated muscle alpha-TM is the major isoform expressed in the heart. The expression of striated muscle beta-TM in the murine myocardium results in a decreased rate of relaxation and increased myofila...
  19. An Internal Domain of Beta Tropomyosin Increases Myofilament Calcium Sensitivity

    Biophysical Journal 96(3):504a (2009)

  20. Molecular and Functional Characterization of a Novel Cardiac Specific Human Tropomyosin Isoform

    Biophysical Journal 96(3):224a (2009)